Zachary Boyd
- Oncology top 1%
- Immunology top 2%
- Molecular Biology top 10%
- Cancer Research top 2%
- Surgery top 5%
- Co-authors
- Priti S. HegdeGregg FineYohann LoriotDaniel P. PetrylakJoaquim BellmuntThomas PowlesNicholas J. VogelzangHoward A. Burris
- Topics
- Cancer Immunotherapy and Biomarkers (16 papers)Bladder and Urothelial Cancer Treatments (9 papers)Ferroptosis and cancer prognosis (6 papers)
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Zachary Boyd
26 papers receiving 3.6k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 2.3k
- Immunology 1.2k
- Molecular Biology 1.1k
- Cancer Research 731
- Surgery 705
Countries citing papers authored by Zachary Boyd
This map shows the geographic impact of Zachary Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zachary Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zachary Boyd more than expected).
Fields of papers citing papers by Zachary Boyd
This network shows the impact of papers produced by Zachary Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zachary Boyd. The network helps show where Zachary Boyd may publish in the future.
Co-authorship network of co-authors of Zachary Boyd
This figure shows the co-authorship network connecting the top 25 collaborators of Zachary Boyd. A scholar is included among the top collaborators of Zachary Boyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zachary Boyd. Zachary Boyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 57 | |
| 2 | Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomabreakdown → | 274 |
| 3 | 12 | |
| 4 | 68 | |
| 5 | 81 | |
| 6 | 1 | |
| 7 | 9 | |
| 8 | 36 | |
| 9 | 11 | |
| 10 | 10 | |
| 11 | 10 | |
| 12 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerbreakdown → | 1850 |
| 13 | 1 | |
| 14 | 12 | |
| 15 | 118 | |
| 16 | 385 | |
| 17 | 51 | |
| 18 | 29 | |
| 19 | 223 | |
| 20 | IL-10 Promotes Survival of Retinal Ganglion Cells without Activating Akt and STAT Signaling Pathways | 1 |
About Zachary Boyd
Zachary Boyd is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 27 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Ferroptosis and cancer prognosis (6 papers). The work is most often cited by research in Oncology (2.3k citations), Immunology (1.2k citations) and Cancer Research (731 citations). Zachary Boyd has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Priti S. Hegde, Gregg Fine, Yohann Loriot, Daniel P. Petrylak, Joaquim Bellmunt, Thomas Powles, Nicholas J. Vogelzang, Howard A. Burris, Xiaodong Shen and Cristina Cruz. Their work appears in journals such as Nature, Journal of Clinical Oncology and Immunity.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.